Rapport Therapeutics, Inc. RAPP R2KR3KPHARMA
Company Overview
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +66.22% |
| 6 Months: | -29.08% |
| 3 Months: | -38.45% |
| 1 Month: | -23.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 50.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RAPP Rapport Therapeutics, Inc. R2KR3KPHARMA | 25.93 | -8.56 | $1.24B | 0.00% | -25.36% | -39.96% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | - | - | 20.00M | 0 |
| Operating Income | - | -6.63M | -9.56M | -17.09M | -20.80M | -21.64M | -27.11M | -29.50M | -29.99M | -24.21M | -60.81M |
| Net Income | -6.15M | -6.41M | -8.71M | -22.67M | -18.12M | -17.54M | -24.06M | -26.73M | -26.93M | -19.86M | -56.62M |
| Diluted EPS | - | -4.45 | -5.70 | -11.07 | -1.70 | -0.50 | -0.68 | -0.75 | -0.71 | -0.42 | -1.19 |
| R&D Expense | - | 4.72M | 7.58M | 12.50M | 15.69M | 15.54M | 19.57M | 22.68M | 22.28M | 32.72M | 51.41M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -36.18M | -83.06M | -125.10M |
| Net Income | -34.79M | -78.31M | -111.48M |
| Diluted EPS | -23.10 | -3.78 | -2.86 |
| R&D Expense | 28.00M | 60.94M | 94.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 31.60M | 155.42M | 314.93M | 512.43M |
| Current Assets | 31.27M | 150.87M | 309.80M | 498.56M |
| Cash & Equivalents | 31.16M | 70.17M | 56.80M | 52.65M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 41.66M | 181.06M | 9.51M | 27.78M |
| Current Liabilities | 1.66M | 8.80M | 8.77M | 19.05M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 2.15M | 1.48M | 11.48M |
| Total Equity | -10.06M | -25.63M | 305.43M | 484.65M |
| Shares Outstanding | 35.38M | 35.38M | 36.58M | 47.77M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -27.18M | -64.83M | -87.47M |
| Investing Cash Flow | -78.86M | -170.14M | -187.47M |
| Financing Cash Flow | 145.14M | 221.62M | 270.79M |
| Capital Expenditure | -1.64M | -2.40M | -616.00K |
| Free Cash Flow | -28.82M | -67.23M | -88.09M |
| Net Change in Cash | 39.09M | -13.34M | -4.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 135.7% | -25.6% | -23.0% |
| ROCE % | -24.7% | -27.1% | -25.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.95% | 7.17M | $219.85M |
| 2 | Trv Gp V, LLC | 13.09% | 6.28M | $192.50M |
| 3 | Arch Venture Management, Llc | 7.77% | 3.73M | $114.29M |
| 4 | Capital International Investors | 6.09% | 2.92M | $89.56M |
| 5 | Goldman Sachs Group Inc | 6.07% | 2.91M | $89.21M |
| 6 | Blackrock Inc. | 5.63% | 2.70M | $82.75M |
| 7 | Cormorant Asset Management, LP | 5.54% | 2.66M | $81.45M |
| 8 | Sofinnova Investments, Inc. | 3.97% | 1.90M | $58.37M |
| 9 | Johnson & Johnson | 3.72% | 1.78M | $54.70M |
| 10 | Polar Capital Holdings PLC | 3.35% | 1.61M | $49.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RAPP
Rapport Therapeutics, Inc. RAPP Stock Forecast & Price Target - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNVzZtSDZnalBNY1VXTFZadXlzZl84MDFlbzRzT1Rpb2o3OEFIekw5a2lHcFdoMmNkdHY5YzMySGNZX1hRSXRGMmdjc1ZnMmhLZXRHdEg2eXZSS0FyNWVSUGh4dnFUQWpDTEhRU1gySkt4c012TDNrQ1h3RHhFbkhYOFpqdThPN2pJYUE?oc…
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQZGVHZ0VDUDlYNW5PTlE5WjF6eXV1MFNBeDJvSGdFSkNyR3FXY2hLU2c5OGx6eG9vcHQ2SnhRbnRncHlRaEpHVUpqUHJ4TUVMWFotUUNVYnlLRDNRdUhSQXdYR2VIdE9oUnZ0LVd2RGt1elNzaGdfRUhXZkpXR1FoSkJEdVFzWUVUMzBCVU…
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study - TradingView
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxOMVNfRjNwZVV4eXdzQXQ0QkxFLUxIUzNobkh4OWdGQ0NiRFg3d3J3ZlVKN3BIYUVtQ0UzYjlCQWM3VnlaRU5yYXBhRldoMlJZTElWd1RZeFpUT2tYVE1DX0owTnFHZi0xNmhpQXRnUk9JMFNnTE9HZnJSZ1p3aDc3MF93dEVhUGkxOFhjTm…
Rapport Therapeutics (RAPP) Stock Seems Pricey Following A 29% Monthly Slide - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOWW1nR0dlUUM4ckVkR2lqQnlQSWgxWG1mOGlpeDNfVmVsSTdWaThrNXNMWTlKaV8xcllUYnBSMTJIOHNVVDRQQW4yN3liNmN0R0JxTHpwbGZLSmsySjlyMTRxOS1EeTZRN0lpYnd3M1FPUWJ1M2hDWjV3cy1JbHdrakZIWTh3MC1CVEh2dX…
Why Is Rapport Therapeutics Stock Trading Higher Today? - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQN0FFOTZmbUZEeDNnVWV5QVMyWHgzcmczWmZaWHNGanpNZXlHcG9iblhaTEgwZnBRQk56enNNV0FULWJRQUdROFZUeFZqYTZMNHVtdnRHUnBvWGtZRUxLZW51OFltRHpHT19MMDJfczVOSUExTjdCWFpLcGhwUThKVkRlRjJIal91X3hHSV…
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPRklTWHJCcFJjNzYxdWN6aDFPVjVxOHJxZnVxajREdTc4UzR2M0YtZEhNTkVmamdNcDhzckZGT2VDbk10eGkwR2VINVRUcUJGLTBiRFo0ZWhWNkkwRHZJamkxdTlpODY0aTItZGJPeFJkd1VHb0QxSlF2bzFEUUJ4RnlWYVk2bm5oZHBKRk…
RAPP — Frequently Asked Questions
What is the current share price of Rapport Therapeutics, Inc. (RAPP)?
As of 2026-10-23 16:27 PDT, Rapport Therapeutics, Inc. (RAPP) trades at $25.93 on NasdaqGM. Its 52-week range is $14.24 to $52.50.
What is the market capitalisation of RAPP?
Rapport Therapeutics, Inc. (RAPP) has a market capitalisation of $1.24B on NasdaqGM.
What is the P/E ratio of RAPP?
RAPP trades at a trailing price-to-earnings (P/E) ratio of -8.56. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.59.
What is the return on equity (ROE) of RAPP?
RAPP has a return on equity (ROE) of -39.96%. Its return on capital employed (ROCE) is -25.36%.
Is RAPP a good stock to buy?
This page provides a data-driven analysis of Rapport Therapeutics, Inc. (RAPP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.